Drugmakers voluntarily withdraw pergolide products

Share this article:
Manufacturers of the Parkinson’s drug pergolide have decided to voluntarily withdraw their products from the US market because of potential damage to patients' heart valves. The products being withdrawn are Permax, the trade name for pergolide marketed by Valeant Pharmaceuticals and two generic pergolide versions manufactured by Par Pharmaceutical and Teva Pharmaceutical Industries. Pergolide is in a class of drugs called dopamine agonists and is used with levodopa and carbidopa medications to manage tremors and slowness of movement in Parkinson’s disease patients. In 2006, an estimated 12,000 patients received prescriptions for pergolide from retail pharmacies in the US. Permax was first approved in 1988 for Eli Lilly as an adjunctive therapy with levodopa in Parkinson’s disease patients. In 2003, the FDA asked for valvulopathy (abnormality of cardiac valves) to be added to the warnings section of Permax labeling, at which time a Dear Healthcare Practitioner letter was issued by Lilly. In 2006, the warning was upgraded to a “black box” status, due to new data concerning risks of heart valve damage. Two recent New England Journal of Medicine studies confirmed previous findings associating pergolide with increased chance of regurgitation (backflow of blood) of the mitral, tricuspid and aortic valves of the heart, the FDA said. The agency said its is working with pergolide manufacturers to see if it remains possible to make the drug available under an Investigational New Drug Application for those few patients receiving pergolide and who cannot be successfully converted to other available treatments.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.